Efficacy of topical niacinamide in graded concentrations on skin health metrics in Indian women-A randomized, parallel-group, clinical trial. - NA

asons India Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1.Female of 18 to 40 years, willing to give a written informed consent and come for regular observations;
•2.Subject with dull complexion, dry/oily skin with/ without uneven texture, and with at least 2 hyperpigmentary spots as a result of photodamage;
•3.Subject has not participated in a similar clinical investigation in the past three months;
•4.Subject who is willing to abstain from using any fairness product, natural/ Ayurvedic treatments or other home remedies and also willing to abstain from undergoing any facial treatments;
•5.The subject should use a light moisturizer followed by broad-spectrum sunscreen for daily use along with an investigational product;
•6.Willingness to complete questionnaires, records, and diaries associated with the study and to complete all visits.

•1.Participants with any chronic illness or any clinical condition;
•2.Participants who have used a Niacinamide USP (GLOShine B3™) in the past 1 month and those who had taken high doses of vitamin C (Greater than or equal to 500 mg a day) or any other antioxidant product in the past 1 month;
•3.Participants who have done any topical, systemic, laser, and surgical treatment on face during the previous year;
•4.Participants with known allergies or sensitivities to niacinamide or associated substances;
•5.Those having a history of skin cancers, especially melanoma;
•6.People with specific preexisting skin disorders or diseases. This might include, aggressive acne, eczema, or disorders like psoriasis;
•7.Participation in other clinical trials in last 90 days prior to screening;
•8.Females who are pregnant and have a positive urine pregnancy test/planning to be pregnant/lactating or not using reliable methods of contraception;
•9.Any condition that could, in the opinion of the investigator, preclude the participants ability to complete the study or that may confound study outcomes;
•10.Participants who show hypersensitivity or allergic reactions after a patch test of the investigational product (observe for 24 hours).

发起方

asons India Pvt. Ltd.